• Amarin Corp. plc, of Dublin, Ireland, received a notices of allowance for Amarin's U.S. Patent application No. 12/815,569 titled "Compositions and Methods for Lowering Triglycerides Without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy"; No. 13/272,520, "Compositions and Methods for Lowering Triglycerides"; and No. 13/349,157, No. 13/458,496, No. 13/614,129 and No. 13/614,146, all related to Vascepa (icosapent ethyl).

• BioChemics Inc., of Danvers, Mass., was issued U.S. Patent No. 8,343,486, "Methods and Composition for Topical Treatment of Medical Conditions Including Wounds and Inflammation"; and No. 8,354,116, "Bifunctional Synthetic Molecules," which is related to its drug-delivery technology, BSM.

• Cyclacel Pharmaceuticals Inc., of Berkeley Heights, N.J., was issued U.S. Patent No. 8,349,792, related to the company's sapacitabine product used in combination with HDAC inhibitors for treating hematological malignancies and solid tumors.

• Hadasit Bio-Holdings Ltd., of Jerusalem, said its portfolio company, KAHR Medical Ltd., was issued U.S. Patent No. 8329657 for KAHR-101, which is being studied in animal models for treating various cancers, arthritis and multiple sclerosis.

• Mesoblast Ltd., of Melbourne, Australia, was issued U.S. Patent No. 7,122,178, No. 8,158,118 and No. 8,367,405, related to its Mesenchymal Precursor Cell adult stem cell technology platform.

• MiMedx Group Inc., of Kennesaw, Ga., was issued U.S. Patent No. 8,357,403, "Placental Tissue Grafts"; No. 8,372,437, "Improved Placental Tissue Grafts"; No. 8,372,438, "Method For Inhibiting Adhesion Formation Using Improved Placental Grafts"; and No. 8,372,439, "Method For Treating a Wound Using Improved Placental Tissue Graft." All are related to MiMedx's placental tissue allografts, including AmnioFix and EpiFix.

• Neurocrine Biosciences Inc., of San Diego, was issued U.S. Patent No. 8,357,697 for the method of treating hyperkinetic movement disorders with NBI-98854, a vesicular monoamine transporter 2 inhibitor.